Catalyst settles FIRDAPSE patent suit with Lupin; generic entry delayed to Feb 2035

CATALYST PHARMACEUTICALS, INC.

Lupin receives license to market generic FIRDAPSE no earlier than February 25, 2035, if FDA-approved.
All pending patent litigation between Catalyst/SERB and Lupin will be terminated.
Previous settlements reached with Teva Pharmaceuticals and Inventia Healthcare Limited.
Ongoing FIRDAPSE patent litigation against Hetero remains active.
Confidential settlement agreement to be submitted to FTC and DOJ for review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.